Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Mackensen

Showing results (191-200 of 196) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 196 results.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
The Journal of Experimental Medicine|November 10, 2020
A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FASMaria Elena Maccari, Sebastian Fuchs, Patrick Kury, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 14, 2013
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"Annette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Nature Cancer|May 13, 2024
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndromeJanaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, et al.
Nature Medicine|April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine|February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Pageof 20

Showing results (191-200 of 196) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 196 results.
The Lancet. Oncology|November 10, 2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trialChristoph Röllig, Hubert Serve, Andreas Hüttmann, et al.
The Journal of Experimental Medicine|November 10, 2020
A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FASMaria Elena Maccari, Sebastian Fuchs, Patrick Kury, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 14, 2013
Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma"Annette Pflugfelder, Corinna Kochs, Andreas Blum, et al.
Nature Cancer|May 13, 2024
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndromeJanaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, et al.
Nature Medicine|April 11, 2018
Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Nature Medicine|February 13, 2018
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cellsNimitha R Mathew, Francis Baumgartner, Lukas Braun, et al.
Pageof 20